Open Access

Analysis on distribution features and drug resistance of clinically isolated Acinetobacter baumannii

  • Authors:
    • Guangming Ren
    • Min Zhou
    • Ning Ding
    • Ning Zhou
    • Qingling Li
  • View Affiliations

  • Published online on: July 11, 2016     https://doi.org/10.3892/etm.2016.3513
  • Pages: 1715-1718
  • Copyright: © Ren et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of the present study was to examine the clinical distribution and drug resistance of Acinetobacter baumannii infection, and provide evidence of clinical medication as well as the prophylaxis for the treatment of drug resistance bacteria. In total, 306 Acinetobacter baumanniis selected from routine culture were collected between January 2012 and December 2013, to analyze the distributions among clinical specimens and wards and their drug resistance state. Of the 306 Acinetobacter baumanniis, the main distribution of specimens was sputum, accounting for 77.78%. The distribution of administrative office was dominated by intensive care unit with a proportion of 40.0% in 2012, which rapidly increased to 60.9% in 2013, followed by neurosurgery, respiration medicine and orthopedics with proportions of 23, 12 and 9.0% in 2012 and 9.71, 8.74 and 3.88% in 2013, respectively. The Acinetobacter baumannii's drug resistance rate of Tazobactam and Piperacillin was increased from 68.0% in 2012 to 71.36% in 2013. At the same time, the drug resistance rate of imipenem was enhanced from 66.0% in 2012 to 72.81% in 2013. By 2013, the drug resistance rates of penbritin, ceftizoxime, cefotetan and macrodantin reached ≤100%. In conclusion, Acinetobacter baumannii mainly causes respiratory tract infection with severe drug resistance. The drug resistance of Acinetobacter baumannii was mainly manifested as multidrug resistance or even pan‑drug resistance with an obvious increasing trend of tolerance. Thus, it is necessary to prevent and treat nosocomial infection, to minimize usage of antibiotics and to standardize medical operating, to reduce the increase in persistence.
View References

Related Articles

Journal Cover

September-2016
Volume 12 Issue 3

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Ren G, Zhou M, Ding N, Zhou N and Li Q: Analysis on distribution features and drug resistance of clinically isolated Acinetobacter baumannii. Exp Ther Med 12: 1715-1718, 2016
APA
Ren, G., Zhou, M., Ding, N., Zhou, N., & Li, Q. (2016). Analysis on distribution features and drug resistance of clinically isolated Acinetobacter baumannii. Experimental and Therapeutic Medicine, 12, 1715-1718. https://doi.org/10.3892/etm.2016.3513
MLA
Ren, G., Zhou, M., Ding, N., Zhou, N., Li, Q."Analysis on distribution features and drug resistance of clinically isolated Acinetobacter baumannii". Experimental and Therapeutic Medicine 12.3 (2016): 1715-1718.
Chicago
Ren, G., Zhou, M., Ding, N., Zhou, N., Li, Q."Analysis on distribution features and drug resistance of clinically isolated Acinetobacter baumannii". Experimental and Therapeutic Medicine 12, no. 3 (2016): 1715-1718. https://doi.org/10.3892/etm.2016.3513